The proliferative capacity of smooth muscle cells (SMC) during neointima formation is prevented by everolimuscoated drug-eluting stents. 
. Although everolimus potently inhibits neointima formation (6) and SMC proliferation (7), the detailed molec- (9) . Considering this controversy, the precise mechanisms by which commonly implanted everolimus-eluting stents prevent in-stent restenosis remain elusive.
By maintaining the stability of telomeres, repetitive deoxyribonucleic acid (DNA)-protein complexes that protect the ends of chromosomes, telomerase is rate limiting for cell proliferation and tissue renewal (10).
Overexpression of the catalytic subunit telomerase reverse transcriptase (TERT) confers a virtually unlimited replicative capacity (11) . In contrast, most somatic cells are thought to repress TERT, resulting in telomere shortening and limited replicative potential (12) . However, accumulating evidence revealed that TERT is inducible in response to various environmental cues (13) , which enhance proliferative responses during tissue renewal (10). Similarly as in other somatic tissues, we (14) (15) (16) and others (17) have previously reported that TERT expression is induced in proliferating SMC and in response to neointima and atherosclerosis formation. However, whether TERT expression in the vascular wall causes neointima formation and the transcriptional mechanisms by which TERT induces aberrant SMC proliferation remain unknown. Moreover, the possibility that TERT constitutes an alternative molecular target for the RB-independent antiproliferative efficacy of mTOR inhibitors on drug-eluting stents has previously not been investigated. Here, we demonstrate that TERT 
RESULTS

EVEROLIMUS INHIBITS SMC PROLIFERATION AND CELL
CYCLE PROGRESSION. Due to the well-established antimitotic activity of mTOR inhibitors, sirolimus (8) and everolimus (7) constitute primary agents used on first-and second-generation drug-eluting stents, respectively. Therefore, we first evaluated the efficacy of everolimus and sirolimus to inhibit SMC proliferation in vitro. Consistent with a previous study (7) , everolimus dose-dependently inhibited SMC proliferation ( Figure 1A) . Compared with everolimus, the previously reported antiproliferative efficacy of sirolimus (8) was limited to higher equimolar doses ( Figure 1B) . To further determine the mechanism by which everolimus prevents SMC proliferation, we next examined cell cycle distribution. As depicted in Figure 1C , everolimus inhibited mitogen-induced G1/S phase progression. On the basis of this finding, we investigated whether everolimus suppressed phosphorylation of the RB protein as the rate-limiting step for G1/S-phase progression. RB phosphorylation releases the transcription factor E2F, which in turn activates target genes required for DNA synthesis (19) . However, surprisingly, everolimus inhibited neither site-specific ser807/811 nor total phosphorylation of the RB protein ( Figure 1D ), although it caused potent inhibition of G1/S-phase progression. These results indicate that everolimus inhibits cell cycle progression through a mechanism independent of RB phosphorylation.
EVEROLIMUS INHIBITS SMC PROLIFERATION THROUGH TRANSCRIPTIONAL REPRESSION OF TELOMERASE.
Whereas RB phosphorylation promotes cell proliferation through release of the S-phase transcription factor E2F, telomerase overexpression endows cells with an unlimited replicative potential by overcoming the limitations of senescence (10,11). Although this mitogenic activity of telomerase was long thought to result from its ability to maintain telomeres, recent evidence indicates that TERT enhances proliferation through mechanisms independent of telomere elongation (20, 21) . Considering this evidence and our previous observation that telomerase is required for SMC proliferation (14, 15) , we hypothesized that the antimitotic activity of everolimus may depend on the repression of TERT. To address this question, we evaluated the antiproliferative efficacy of everolimus in SMC isolated from mice overexpressing a murine TERT transgene (18) . As depicted in Figure 2A , 
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Telomerase Targeting by Everolimus supported not only by our data demonstrating that TERT overexpression induces histone acetylation at E2F target sites, but also by previous work, in which TERT has been suggested to activate the chromatin at Wnt-dependent promoters in stem cells (22) .
Interestingly, TERT itself appears to be recruited to chromatin at selective transcription factor binding sites, where it associates with chromatin-modifying proteins (22) . Alternatively, TERT may increase E2F binding through protein stabilization at the chromatin, which has recently been reported for myc-dependent gene transcription (29) . Therefore, characterization of the specific chromatin signature at TERT-activated transcription sites will be necessary in future studies to determine the detailed mechanisms by which TERT modulates gene transcription.
CONCLUSIONS
We identified TERT as a previously unrecognized activator of an S-phase gene expression program.
In response to mitogenic stimulation, TERT facilitates 
